1. Home
  2. GEVO vs FULC Comparison

GEVO vs FULC Comparison

Compare GEVO & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gevo Inc.

GEVO

Gevo Inc.

HOLD

Current Price

$1.53

Market Cap

421.1M

Sector

Industrials

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$3.65

Market Cap

467.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GEVO
FULC
Founded
2005
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
421.1M
467.8M
IPO Year
2010
2019

Fundamental Metrics

Financial Performance
Metric
GEVO
FULC
Price
$1.53
$3.65
Analyst Decision
Buy
Buy
Analyst Count
3
8
Target Price
$6.58
$16.38
AVG Volume (30 Days)
2.9M
4.2M
Earning Date
05-07-2026
04-27-2026
Dividend Yield
N/A
N/A
EPS Growth
58.82
N/A
EPS
N/A
N/A
Revenue
$711,000.00
N/A
Revenue This Year
$19.44
N/A
Revenue Next Year
$5.59
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.12
$2.83
52 Week High
$2.97
$15.74

Technical Indicators

Market Signals
Indicator
GEVO
FULC
Relative Strength Index (RSI) 39.42 31.56
Support Level N/A $2.83
Resistance Level $1.93 $8.18
Average True Range (ATR) 0.09 0.27
MACD -0.01 0.02
Stochastic Oscillator 30.39 19.33

Price Performance

Historical Comparison
GEVO
FULC

About GEVO Gevo Inc.

Gevo Inc is a growth-oriented company that focuses on hard to decarbonize market sectors such as jet fuel, certain specialty fuels, on-road fuels, chemicals and materials, and certain products for the food chain such as protein and feeds made as co-products from its processes. It produces and sells competitively priced, renewable, drop-in products for these sectors, and generate carbon abatement value through its plant design and business systems. It owns and operates an ethanol plant with an adjacent CCS facility, Class VI carbon-storage well, and others. The group is currently developing the world's first large-scale ATJ facility to be co-located at the North Dakota site.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: